INVESTIGACIÓN ORIGINAL / ORIGINAL RESEARCH
Chachaima-Mar J. y col.
Rev Med Hered. 2020; 31:235-241
241
Perl inmunofenotípico de cáncer de mama de
pacientes atendidas en un hospital general de Lima, Perú
Bordoni A. Breast cancer classication according
to immunohistochemical markers: Clinicopathologic
features and short-term survival analysis in a
population-based study from the South of Switzerland.
Ann Oncol. 2009; 20(4):628-35.
8. Polley MYC, Freidlin B, Korn EL, Conley BA,
Abrams JS, McShane LM. Statistical and practical
considerations for clinical evaluation of predictive
biomarkers. J Natl Cancer Inst. 2013; 105(22):1677-
83.
9. Colomer R, Aranda-López I, Albanell J, et al.
Biomarkers in breast cancer: A consensus statement
by the Spanish Society of Medical Oncology and the
Spanish Society of Pathology. Clin Transl Oncol.
2017; 1:1-12.
10. Duggan C, Dvaladze AL, Tsu V, et al. Resource-
stratied implementation of a community-based
breast cancer management programme in Peru.
Lancet Oncol. 2017; 18(10):e607-17.
11. Sali AP, Sharma N, Verma A, et al. identication of
luminal subtypes of breast carcinoma using surrogate
immunohistochemical markers and ascertaining
their prognostic relevance. Clin Breast Cancer. 2020;
20(5):382-9.
12. Vallejos C, Gómez H, Cruz W, et al. Breast cancer
classication according to immunohistochemistry
markers: Subtypes and association with
clinicopathologic variables in a peruvian hospital
database. Clin Breast Cancer. 2010; 10(4):294-300.
13. Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-
Arias M, Doimi F, Neciosup SP, et al. PIK3CA
mutations in Peruvian patients with HER2-amplied
and triple negative non-metastatic breast cancers.
Hematol Oncol Stem Cell Ther. 2014; 7(4):142-8.
14. Salive ME. Referral bias in tertiary care: the utility of
clinical epidemiology. Mayo Clin Proc. 1994;
69(8):808-9.
15. Lee H-C, Ko H, Seol H, et al. Expression of
immunohistochemical markers before and after
neoadjuvant chemotherapy in breast carcinoma, and
their use as predictors of response. J Breast Cancer.
2013; 16(4):395-403.
16. Lester SC, Hicks DG. Diagnostic Pathology:
Breast. 2nd edition. New York: Elsevier; 2016.
(Citado el 25 de septiembre de 2020) Disponible en:
https://www.elsevier.com/books/diagnostic-
pathology-breast/lester/978-0-323-75895-6
17. Dowsett M, Nielsen TO, A’Hern R, et al. Assessment
of Ki67 in breast cancer: recommendations from the
International Ki67 in Breast Cancer working group. J
Natl Cancer Inst. 2011; 103(22):1656-64.
18. Wolff AC, Hammond MEH, Allison KH, et al. Human
Epidermal Growth Factor Receptor 2 Testing in Breast
Cancer: American Society of Clinical Oncology/
College of American Pathologists Clinical Practice
Guideline Focused Update. J Clin Oncol. 2018;
36(20):2105-22.
19. Allison KH, Hammond MEH, Dowsett M, et al.
Estrogen and progesterone receptor testing in breast
cancer: ASCO/CAP Guideline Update. J Clin Oncol.
2020; 38(12):1346-66.
20. Fitzgibbons PL, Bartley AN, Connolly JL, et al.
Template for reporting results of biomarker testing
of specimens from patients with carcinoma of the
breast. Arch Pathol Lab Med. 2014; 138(5):595-601.
doi: 10.5858/arpa.2013-0566-CP
21. Sinn HP, Kreipe H. A brief overview of the WHO
classication of breast tumors, 4th edition, focusing
on issues and updates from the 3rd edition. Breast
Care. 2013; 8(2):149-54.
22. Cardoso F, Kyriakides S, Ohno S, et al. Early breast
cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up†. Ann Oncol.
2019; 30(8):1194-220.
23. Caldas C, Stingl J. Molecular heterogeneity of breast
carcinomas and the cancer stem cell hypothesis. Nat
Rev Cancer. 2007; 7(10):791-9.
24. Li CI, Uribe DJ, Daling JR. Clinical characteristics of
different histologic types of breast cancer. Br J
Cancer. 2005; 93(9):1046-52.
25. Arturo G, Bueno M. Características clínicas y
pronósticas de los subtipos moleculares de cáncer de
mama determinados por inmunohistoquímica.
Arequipa, Perú. Rev Peru Med Exp Salud Publica.
2016; 34(3):472-8.
26. Kontzoglou K, Palla V, Karaolanis G, et al.
Correlation between Ki67 and Breast Cancer
Prognosis. Oncol Switz. 2013; 84(4):219-25.
27. Howlader N, Altekruse SF, Li CI, et al. US incidence
of breast cancer subtypes dened by joint hormone
receptor and HER2 status. J Natl Cancer Inst. 2014;
106(5). Doi: http://dx.doi.org/10.1093/jnci/dju055
28. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab
containing regimens for early breast cancer. Cochrane
Database Syst Rev. 2012; 2012(4):CD006243. doi:
10.1002/14651858.CD006243.pub2.
29. Setyawati Y, Rahmawati Y, Widodo I, Ghozali A,
Purnomosari D. The association between molecular
subtypes of breast cancer with histological grade and
lymph node metastases in Indonesian Woman. Asian
Pac J Cancer Prev. 2018; 19(5):1263-8.
30. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN.
Breast cancer subtypes based on ER/PR and Her2
expression: comparison of clinicopathologic features
and survival. Clin Med Res. 2009; 7(1-2):4-13.
31. Yang XR, Sherman ME, Rimm DL, et al. Differences
in risk factors for breast cancer molecular subtypes
in a population-based study. Cancer Epidemiol
Biomark Prev. 2007; 16(3):439-43.
Recibido: 28/01/2020
Aceptado: 30/09/2020